Cost thresholds for anticipated long‐acting HIV pre‐exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study
Journal of the International AIDS Society · 2025
DOI: 10.1002/jia2.26427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von David Kaftan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health, New York University Grossman School of Medicine, New York, New York, 10016, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Investment Foundation Fund (CIFF), Bill & Melinda Gates Foundation, US National Institutes of Health.
Abstract (Originalsprache)
Introduction
Affordable HIV prevention tools are needed in Eastern and Southern Africa (ESA). Several promising long‐acting pre‐exposure prophylaxis (LA‐PrEP) products are available or in development. However, ESA settings face severe healthcare resource constraints. We aimed to estimate the threshold price at which LA‐PrEP products could be cost‐effective in three ESA settings.
Methods
We adapted an agent‐based model, EMOD‐HIV, to simulate LA‐PrEP (monthly oral, 2‐ and 6‐monthly injectable) rollout in South Africa, Zimbabwe and Kenya. Due to uncertainties about LA‐PrEP use, we examined a range of coverages (5%−20% of HIV‐negative sexually active adults) and extents to which LA‐PrEP use will be concentrated among those most at risk (prioritized rollout from higher‐ to lower‐risk groups vs. uniform rollout among sexually active adults). To evaluate a 20‐year commitment to LA‐PrEP delivery, we assumed LA‐PrEP was scaled up to target coverage from 2025 to 2030 and maintained at target levels before ending in 2045. We estimated maximum per‐dose and per‐year LA‐PrEP costs that achieve cost‐effectiveness (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Population Health, New York University Grossman School of Medicine, New York, New York, 10016, USA.
- Department of Global Health, University of Washington, Seattle, Washington, USA.
- Clinton Health Access Initiative, Boston, Massachusetts, USA.
- University of South Africa, Pretoria, South Africa.
ORCID-Profile: Monisha Sharma, Danielle Resar, Edinah Mudimu, Linxuan Wu, Hae-Young Kim, Sarah Jenkins, Anna Bershteyn
Förderung
- Children's Investment Foundation Fund (CIFF)
- Bill & Melinda Gates Foundation
- US National Institutes of Health
- NIAID NIH HHS
- Gates Foundation
Zitieren
APA
Kaftan, D., Sharma, M., Resar, D., Milali, M., Mudimu, E., Wu, L., Arrouzet, C., Platais, I., Kim, H. Y., Jenkins, S., & Bershteyn, A. (2025). Cost thresholds for anticipated long‐acting HIV pre‐exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26427
Vancouver
Kaftan D, Sharma M, Resar D, Milali M, Mudimu E, Wu L, et al. Cost thresholds for anticipated long‐acting HIV pre‐exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.26427
BibTeX
@article{Kaftan2025,
author = {Kaftan, David and Sharma, Monisha and Resar, Danielle and Milali, Masabho and Mudimu, Edinah and Wu, Linxuan and Arrouzet, Cory and Platais, Ingrida and Kim, Hae-Young and Jenkins, Sarah and Bershteyn, Anna},
title = {Cost thresholds for anticipated long‐acting HIV pre‐exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study},
journal = {Journal of the International AIDS Society},
year = {2025},
doi = {10.1002/jia2.26427}
}
EUVIMED